Actively Recruiting
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
Led by China-Japan Friendship Hospital · Updated on 2025-09-22
150
Participants Needed
1
Research Sites
573 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
CONDITIONS
Official Title
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospitalized between Jan 1, 2016 and Dec 31, 2026
- Diagnosed with Takayasu's arteritis according to the modified Ishikawa criteria, 1990 American College of Rheumatology criteria, or 2022 ACR/EULAR criteria
- Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography
- Patients without aortic or primary branch involvement who show clinical features and CT-confirmed pulmonary artery involvement after excluding other causes of pulmonary artery stenosis or occlusion
You will not qualify if you...
- Patients with pulmonary artery involvement caused by diseases other than Takayasu's arteritis, such as other vasculitis types, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis, or chronic thromboembolic pulmonary hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China-Japan Friendship hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
W
Wanmu Xie, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here